Moomoo AIのまとめ
Mangoceuticals, Inc. has reported its financial performance for the year ended December 31, 2023, with revenues totaling $731,493 and a net loss of $9,212,417. The company's accumulated deficit has reached $11,228,173. Earlier in the year, Mangoceuticals completed an initial public offering (IPO) in March, raising approximately $4.35 million by issuing 1,250,000 shares at $4.00 each. Additionally, a follow-on offering was conducted, involving the sale of 4,600,000 shares and the issuance of warrants to Boustead Securities, LLC. The company has also entered into consulting agreements, compensating with restricted common stock, and borrowed funds from entities controlled by CEO Jacob D. Cohen, with the borrowed amounts being payable on demand without interest. Furthermore, stockholders have approved an amendment to the 2022 Equity Incentive Plan, increasing the number of shares available for awards. Despite the financial challenges, as indicated by the substantial doubt about the company's ability to continue as a going concern, Mangoceuticals has prepared its financial statements on a going concern basis and is not currently involved in any litigation that could impact its operations.
Mangoceuticals, Inc. has reported its financial performance for the year ended December 31, 2023, with revenues totaling $731,493 and a net loss of $9,212,417. The company's accumulated deficit has reached $11,228,173. Earlier in the year, Mangoceuticals completed an initial public offering (IPO) in March, raising approximately $4.35 million by issuing 1,250,000 shares at $4.00 each. Additionally, a follow-on offering was conducted, involving the sale of 4,600,000 shares and the issuance of warrants to Boustead Securities, LLC. The company has also entered into consulting agreements, compensating with restricted common stock, and borrowed funds from entities controlled by CEO Jacob D. Cohen, with the borrowed amounts being payable on demand without interest. Furthermore, stockholders have approved an amendment to the 2022 Equity Incentive Plan, increasing the number of shares available for awards. Despite the financial challenges, as indicated by the substantial doubt about the company's ability to continue as a going concern, Mangoceuticals has prepared its financial statements on a going concern basis and is not currently involved in any litigation that could impact its operations.
Mangoceuticals社は2023年12月31日までの決算を発表し、収益が$731,493であり、純損失が$9,212,417であることを報告しました。同社の積み立て赤字は$11,228,173に達しました。Mangoceuticals社は3月に初めての公開株式（IPO）を完了し、1,250,000株を4.00ドルで発行して約435万ドルを調達しました。さらに、フォローオンオファリングが行われ、4,600,000株とBoustead Securities, LLCに契約先証券と割り当てる株式に発行権が与えられました。また、Mangoceuticals社はコンサルティング契約に入り、制限付...すべて展開
Mangoceuticals社は2023年12月31日までの決算を発表し、収益が$731,493であり、純損失が$9,212,417であることを報告しました。同社の積み立て赤字は$11,228,173に達しました。Mangoceuticals社は3月に初めての公開株式（IPO）を完了し、1,250,000株を4.00ドルで発行して約435万ドルを調達しました。さらに、フォローオンオファリングが行われ、4,600,000株とBoustead Securities, LLCに契約先証券と割り当てる株式に発行権が与えられました。また、Mangoceuticals社はコンサルティング契約に入り、制限付き普通株式で報酬を支払い、CEOのJacob D. Cohenが支配するエンティティから資金を借り入れ、利息なしで要求に応じて返済されました。さらに、株主は2022年の株式インセンティブ計画の修正を承認し、受賞用の株式数を増やすことを決定しました。Mangoceuticals社は経営継続の疑念が相当なことを示すにもかかわらず、経営継続方式で財務諸表を準備し、現在、会社の業務に影響を与える可能性のある訴訟に巻き込まれていません。
役に立った
役に立たない
